1 / 21

Ascites and Hepatocellular carcinoma

Ascites and Hepatocellular carcinoma. Curtis Barry, MD UMASS ECHO April 21, 2017. Ascites. The Development of Ascites Revised Underfill. Peripheral vasodilation occurs as the result of decreased hepatic clearance of vasodilators such as glucagon and NO

burtonburton
Download Presentation

Ascites and Hepatocellular carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ascites and Hepatocellular carcinoma Curtis Barry, MD UMASS ECHO April 21, 2017

  2. Ascites

  3. The Development of AscitesRevised Underfill • Peripheral vasodilation occurs as the result of decreased hepatic clearance of vasodilators such as glucagon and NO • The body compensates for the perceived drop in circulating blood volume in two ways: • increased cardiac output • activation of the renin-angiotensin system resulting in increased renal retention of sodium and free water

  4. INITIAL WORKUP OF ASCITES: DIAGNOSIS PARACENTESIS Initial Workup of AscitesDiagnostic Paracentesis Optional Glucose, LDH Amylase Protein/Albumin Routine ? secondary infection ? cirrhotic ascites ? pancreatic ascites PMN count Culture Cytology ? malignant ascites ? SBP

  5. Serum Ascites Albumin GradientSAAG • Best test for classifying ascites into portal hypertensive (SAAG >1.1 g/dL) and non–portal hypertensive (SAAG <1.1 g/dL) causes.

  6. DIAGNOSTIC PARACENTESIS Diagnostic Paracentesis Indications • New-onset ascites • Admission to hospital • Symptoms/signs of SBP • Renal dysfunction • Unexplained encephalopathy Contraindications • None

  7. The Management of Ascites • Dietary measures • Diuretics • Spironolactone • Large volume paracentesis • TIPS • Peritoneovenous shunt • Liver transplantation

  8. Patient • 72 year old male with reported history of cirrhosis due to alcohol. Hasn’t seen a provider in many years presents for a new patient appt.

  9. Hepatocellular Carcinoma

  10. Dual Blood Supply of Liver HCC Diagnosis • The vascular supply of HCC arises from the hepatic artery through neovascularization. • Imaging of the liver has to be performed in a triple phase manner to account for the early arterial phase followed by the portal venous phase and the delayed phases Yu JS, et al, Am J Roentgenol 1999

  11. Why HCC is Rising? HCC Epidemiology Why HCC is Rising? Increasing prevalence of patients with cirrhosis • Rising incidence of cirrhosis • HCV (main reason) • HBV • Other (?NAFLD/insulin resistance) • Improved survival of patients with cirrhosis El-Serag HB, Gastroenterology 2004

  12. Dynamic Imaging Studies 4 Phase Liver CT Quick and easy 1/3 price of MRI Dynamic Contrast Enhanced MRI Longer and more Expensive Different images Biopsy only if imaging NOT “Classic” for HCC

  13. Washout in HCC Washout in HCC HCC Diagnosis Arterial phase 2-min delayed Arterial phase 5-min delayed

  14. HCC - MRI and Surgical Resection Case 1

  15. Resection versus Transplantation HCC Treatment Resection versus Transplantation • TRANSPLANTATION • curative in early stage • advanced cirrhosis • shortage of donor livers • drop-out while awaiting transplantation • higher post-operative mortality; significant morbidity from recurrent hepatitis C • RESECTION • readily available • compensated cirrhosis without significant portal hypertension • high rate of recurrence of HCC

  16. Radiofrequency Ablation for Hepatocellular Carcinoma HCC Treatment Probe insertion Deployment of tines and treatmentof tumor and surrounding region

  17. Radiofrequency Ablation HCC Treatment

  18. Trans Arterial Chemo Embolization (TACE)

  19. Trans-arterial Chemoembolization for Hepatocellular Cancer HCC Treatment

  20. Systemic Therapies for Hepatocellular Cancer HCC Treatment Systemic Therapies for Hepatocellular Cancer • Only Sorafenib is currently approved • Taken orally • Compared to placebo increased overall survival by 37%, which calculated out to 2-3 months for pts with advanced HCC and COMPENSATED cirrhosis. • Main side effects are diarrhea, fatigue and rash on the hands and feets • Other medications are currently being investigated Mazzaferro V, et al, NEJM 2008

  21. Patient • US ordered found to have 3.7cm lesion • MRI 4.8cm lesion • Treated with TACE • Listed for liver transplant

More Related